Form 4: Ardelyx Director Mott Acquires Shares and Options

Ardelyx, Inc. director David Mott acquired shares and stock options under the company's compensation program on June 16, 2026.

Summary

• David Mott, a Director at Ardelyx, Inc., acquired 20,282 shares of common stock and 39,715 stock options on June 16, 2026.
• The shares were received under the Issuer's Non-Employee Director Compensation Program, with Mott electing to receive stock in lieu of cash.
• Additionally, Mott acquired restricted stock units (RSUs) which entitle him to one share of common stock per RSU upon vesting.
• Mott also received a stock option to buy common stock at an exercise price of $5.67, with vesting occurring monthly and accelerating on the next annual stockholder's meeting.
• Following these transactions, Mott beneficially owns 3,349,655 shares of common stock, with 87,566 shares held for entities associated with New Enterprise Associates, for which he disclaims beneficial ownership beyond his pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine director compensation transactions rather than significant strategic or financial performance indicators.

Positives

• Director David Mott's acquisition of shares and options indicates continued commitment and alignment with the company's performance.
• The issuance of shares and options under the Non-Employee Director Compensation Program is a standard practice for incentivizing and retaining directors.

Risks

• The vesting schedule for the stock options and RSUs means that a portion of the compensation is contingent on continued service, creating a potential retention risk if the director's service is interrupted.
• The disclaimer of beneficial ownership for shares held for New Enterprise Associates introduces complexity in understanding the ultimate beneficial ownership structure.

Future Outlook

The stock option granted to David Mott has a vesting schedule that includes acceleration on the date of the next annual stockholder's meeting, subject to continued service.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are common in the biotechnology and pharmaceutical sectors as a means of director compensation and incentive alignment.

Related Party Transactions

• The acquisition of shares and stock options by Director David Mott is part of the Issuer's Non-Employee Director Compensation Program, which is a related party transaction.

Stakeholder Impact

• Shareholders: The transaction reflects standard director compensation practices and does not immediately indicate a change in share structure or value, though future vesting could impact dilution.
• Employees: The compensation program for directors is separate from employee compensation, but signals the company's approach to incentivizing its leadership.
• Management: The transaction reinforces the alignment of director interests with the company's long-term performance through equity ownership.

Next Steps

• Vesting of stock options and RSUs according to the specified schedule.
• Potential acceleration of vesting for unvested options on the date of the next annual stockholder's meeting.

Key Dates

Keywords

Ardelyx, ARDX, Form 4, Insider Trading, Director Compensation, Stock Options, Restricted Stock Units, Beneficial Ownership, SEC Filing